| P2093 | author name string | Karen C Carroll | |
| | Stefan Riedel | |
| | Lisa M Dam | |
| | Tsigereda Tekle | |
| | Stephen W Eisinger | |
| | Kar Mun Neoh | |
| P2860 | cites work | Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 |
| | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 |
| | Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 |
| | Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 |
| | Setting and revising antibacterial susceptibility breakpoints | Q35913176 |
| | Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia | Q36276932 |
| | The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 |
| | Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 |
| | Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? | Q37893331 |
| | The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Q37981103 |
| | Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates | Q38474869 |
| | Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence | Q39008770 |
| | Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of staphylococci and enterococci | Q41483827 |
| | Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus | Q41873909 |
| | Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp. | Q41908540 |
| | Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. | Q41915074 |
| | Susceptibility of enterococci to daptomycin is dependent upon testing methodology | Q42261143 |
| | The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study | Q42272970 |
| | Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci | Q42637617 |
| | Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods | Q43062273 |
| | Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus | Q43097113 |
| | Evidence for daptomycin Etest lot-related MIC elevations for Staphylococcus aureus | Q43275181 |
| | High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 |
| | Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections | Q46431265 |
| | Decreasing incidence of Staphylococcus aureus bacteremia over 9 years: greatest decline in community-associated methicillin-susceptible and hospital-acquired methicillin-resistant isolates | Q46543550 |
| | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 |
| | Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. | Q51785920 |
| | Continued Emergence of USA300 Methicillin-Resistant Staphylococcus aureus in the United States: Results from a Nationwide Surveillance Study | Q56934821 |
| | Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study | Q82644438 |
| | Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009 | Q83215855 |
| | Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study | Q86222628 |
| | Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysis | Q86296397 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| | linezolid | Q411377 |
| | vancomycin | Q424027 |
| P304 | page(s) | 2216-2222 | |
| P577 | publication date | 2014-04-09 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid | |
| P478 | volume | 52 | |